|
|
Vaccine Detail
|
MART-1:27-35 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: MART-1:27-35 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007507
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MLANA
- MLANA
gene engineering:
- Description: A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide. (NCIT_C2775).
|
| Host Response |
|
|
| References |
Insaidoo et al., 2011: Insaidoo FK, Borbulevych OY, Hossain M, Santhanagopolan SM, Baxter TK, Baker BM. Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. The Journal of biological chemistry. 2011; 286(46); 40163-40173. [PubMed: 21937447].
NCIT_C2775: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2775]
|
|
